CU24665B1 - Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden - Google Patents
Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprendenInfo
- Publication number
- CU24665B1 CU24665B1 CU2020000081A CU20200081A CU24665B1 CU 24665 B1 CU24665 B1 CU 24665B1 CU 2020000081 A CU2020000081 A CU 2020000081A CU 20200081 A CU20200081 A CU 20200081A CU 24665 B1 CU24665 B1 CU 24665B1
- Authority
- CU
- Cuba
- Prior art keywords
- chimeric protein
- protein
- receptor
- binding domain
- compositions
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 title abstract 2
- 101710132601 Capsid protein Proteins 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>La invención provee una proteína quimérica que posee una estructura modular y que comprende un dominio de unión al receptor (RBD) de la proteína de la espiga (S) de coronavirus, un segmento con capacidad de unión al antígeno de la nucleocápsida del virus de la hepatitis B (HBcAg), un segmento que comprende la secuencia de aminoácidos HHHHHH, y dos segmentos espaciadores. En la proteína quimérica los segmentos se disponen en un orden específico, y esta tiene la capacidad de formar nanopartículas mixtas con el HBcAg. La proteína quimérica forma parte de composiciones vacunales para la prevención de las infecciones causadas por coronavirus. Por tanto, la invención revela un método de prevención de una infección causada por coronavirus donde se administra una composición vacunal que comprende dicha proteína quimérica.</p>
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000081A CU24665B1 (es) | 2020-11-04 | 2020-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
| JP2023527114A JP2023548205A (ja) | 2020-11-04 | 2021-11-03 | コロナウイルススパイクタンパク質の受容体結合ドメインを含むキメラタンパク質及びその組成物 |
| CA3197024A CA3197024A1 (en) | 2020-11-04 | 2021-11-03 | Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions thereof |
| CN202180088951.7A CN116802194A (zh) | 2020-11-04 | 2021-11-03 | 包含冠状病毒刺突蛋白的受体结合结构域的嵌合蛋白以及包含其的组合物 |
| EP21834711.0A EP4242222A1 (en) | 2020-11-04 | 2021-11-03 | Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising them |
| US18/035,254 US20230405106A1 (en) | 2020-11-04 | 2021-11-03 | Chimeric protein comprising the receptor binding domain of the corona virus spike protein and compositions comprising them |
| PCT/CU2021/050010 WO2022096039A1 (es) | 2020-11-04 | 2021-11-03 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden |
| MX2023005211A MX2023005211A (es) | 2020-11-04 | 2021-11-03 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de coronavirus y composiciones que las comprenden. |
| AU2021373188A AU2021373188A1 (en) | 2020-11-04 | 2021-11-03 | Chimeric protein comprising the receptor binding domain of the coronavirus spike protein and compositions comprising them |
| ARP210103065A AR123998A1 (es) | 2020-11-04 | 2021-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
| CONC2023/0004963A CO2023004963A2 (es) | 2020-11-04 | 2023-04-20 | Proteina quimerica que comprende el dominio de union al receptor de la proteina de la espiga de corona virus y composiciones que las comprenden |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000081A CU24665B1 (es) | 2020-11-04 | 2020-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20200081A7 CU20200081A7 (es) | 2022-06-06 |
| CU24665B1 true CU24665B1 (es) | 2023-06-13 |
Family
ID=79164940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000081A CU24665B1 (es) | 2020-11-04 | 2020-11-04 | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405106A1 (es) |
| EP (1) | EP4242222A1 (es) |
| JP (1) | JP2023548205A (es) |
| CN (1) | CN116802194A (es) |
| AR (1) | AR123998A1 (es) |
| AU (1) | AU2021373188A1 (es) |
| CA (1) | CA3197024A1 (es) |
| CO (1) | CO2023004963A2 (es) |
| CU (1) | CU24665B1 (es) |
| MX (1) | MX2023005211A (es) |
| WO (1) | WO2022096039A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111217918B (zh) * | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
| CN111620952A (zh) * | 2020-06-17 | 2020-09-04 | 苏州米迪生物技术有限公司 | 基于嵌合型病毒样颗粒的新型冠状病毒疫苗 |
| CN111676248A (zh) * | 2020-07-02 | 2020-09-18 | 军事科学院军事医学研究院军事兽医研究所 | 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建 |
-
2020
- 2020-11-04 CU CU2020000081A patent/CU24665B1/es unknown
-
2021
- 2021-11-03 EP EP21834711.0A patent/EP4242222A1/en active Pending
- 2021-11-03 CN CN202180088951.7A patent/CN116802194A/zh active Pending
- 2021-11-03 MX MX2023005211A patent/MX2023005211A/es unknown
- 2021-11-03 CA CA3197024A patent/CA3197024A1/en active Pending
- 2021-11-03 AU AU2021373188A patent/AU2021373188A1/en active Pending
- 2021-11-03 US US18/035,254 patent/US20230405106A1/en active Pending
- 2021-11-03 WO PCT/CU2021/050010 patent/WO2022096039A1/es active Application Filing
- 2021-11-03 JP JP2023527114A patent/JP2023548205A/ja active Pending
- 2021-11-04 AR ARP210103065A patent/AR123998A1/es unknown
-
2023
- 2023-04-20 CO CONC2023/0004963A patent/CO2023004963A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023548205A (ja) | 2023-11-15 |
| AU2021373188A1 (en) | 2023-06-01 |
| EP4242222A1 (en) | 2023-09-13 |
| CN116802194A (zh) | 2023-09-22 |
| CA3197024A1 (en) | 2022-05-12 |
| MX2023005211A (es) | 2023-05-16 |
| AR123998A1 (es) | 2023-02-01 |
| US20230405106A1 (en) | 2023-12-21 |
| CU20200081A7 (es) | 2022-06-06 |
| CO2023004963A2 (es) | 2023-06-20 |
| WO2022096039A1 (es) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
| BR112012018529A2 (pt) | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna | |
| BR112018067964A2 (pt) | agentes antivirais para hepatite b | |
| ECSP14013315A (es) | Inhibidores de aplicación viral | |
| CL2008002995A1 (es) | Compuestos derivados de espiropirrolidina; composicion farmaceutica que los comprende; procedimiento de preparacion de compuestos intermediarios; y su uso para tratar la infeccion del virus de la hepatitis c y del vih. | |
| BR112012000287B8 (pt) | composição farmacêutica para um inibidor de protease viral de hepatite c | |
| UY29068A1 (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan | |
| CL2011000136A1 (es) | Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c. | |
| CL2012001959A1 (es) | Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae. | |
| BR112013026345A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| ECSP13012622A (es) | Compuestos antivirales | |
| CO6761335A2 (es) | Inhibidores del virus de la hepatitis c | |
| UY34066A (es) | Inhibidores del virus de la hepatitis c | |
| CR11248A (es) | Compuestos anti-virales, composiciones y metodos de uso | |
| DOP2021000185A (es) | Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb | |
| CO2022008701A2 (es) | Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter | |
| BR112015005347A2 (pt) | composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids | |
| ECSP22081150A (es) | Composición farmacéutica para la prevención o tratamiento de enfermedad infecciosa viral de arn epidémica | |
| UY39313A (es) | Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| CU24665B1 (es) | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden | |
| SV2005001919A (es) | Compuestos nucleosidos para el tratamiento de infecciones virales | |
| MX2020003473A (es) | Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas. | |
| CO6300847A2 (es) | Compuestos anti-virales composiciones y metodos de uso |